GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

ORIC-114   Click here for help

GtoPdb Ligand ID: 13880

Synonyms: ORIC114
Compound class: Synthetic organic
Comment: ORIC-114 is an advanced, orally bioavailable, brain penetrant EGFR and ERBB2 (HER2) inhibitor that is designed to target these receptor tyrosine kinases with oncogenic exon 20 insertion mutations in metastatic non-small-cell lung cancer and other similarly mutated solid tumours [1].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 3
Rotatable bonds 11
Topological polar surface area 125.34
Molecular weight 674.74
XLogP 1.8
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C=CC(=O)NC1=CC(=C(C=C1N2CCC(CC2)N3CCN(CC3)C4CC4)C(=O)O)NC5=NC=NC(=C5)N6[C@H](CCO6)C7=CC(=CC(=C7)F)F
Isomeric SMILES C=CC(=O)NC1=C(C=C(C(=C1)NC2=CC(=NC=N2)N3[C@H](CCO3)C4=CC(=CC(=C4)F)F)C(=O)O)N5CCC(CC5)N6CCN(CC6)C7CC7
InChI InChI=1S/C35H40F2N8O4/c1-2-34(46)41-29-19-28(40-32-20-33(39-21-38-32)45-30(7-14-49-45)22-15-23(36)17-24(37)16-22)27(35(47)48)18-31(29)44-8-5-26(6-9-44)43-12-10-42(11-13-43)25-3-4-25/h2,15-21,25-26,30H,1,3-14H2,(H,41,46)(H,47,48)(H,38,39,40)/t30-/m1/s1
InChI Key MSIHWUDQPVKDLP-SSEXGKCCSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Junttila MR, Warne R, Repellin C, Sambucetti L, Chang J, Kim S, Kim HY, Shin DG, Park DH, Patel R et al.
1345P Preclinical activity of ORIC-114, a highly selective, brain penetrant, irreversible kinase inhibitor, against atypical mutations in EGFR.
Accessed on 05/05/2025. Modified on 05/05/2025. Annals of Oncology, https://www.annalsofoncology.org/article/S0923-7534(23)03215-5/fulltext